Inozyme Historical Income Statement
| INZY Stock | USD 2.81 0.12 4.46% |
Historical analysis of Inozyme Pharma income statement accounts such as Depreciation And Amortization of 541.8 K or Interest Expense of 3.5 M can show how well Inozyme Pharma performed in making a profits. Evaluating Inozyme Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Inozyme Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Inozyme Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inozyme Pharma is a good buy for the upcoming year.
Inozyme |
About Inozyme Income Statement Analysis
Inozyme Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Inozyme Pharma shareholders. The income statement also shows Inozyme investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Inozyme Pharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Inozyme Pharma. It is also known as Inozyme Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Most accounts from Inozyme Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.At this time, Inozyme Pharma's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 4.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 541.8 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 211K | 1.9M | 4.1M | 4.3M | Net Interest Income | 211K | 1.9M | 4.1M | 4.3M |
Inozyme Pharma income statement Correlations
Click cells to compare fundamentals
Inozyme Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inozyme Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 1.1M | 370K | 211K | 1.9M | 4.1M | 4.3M | |
| Interest Income | 1.1M | 370K | 211K | 1.9M | 4.1M | 4.3M | |
| Depreciation And Amortization | 83K | 217K | 1.1M | 744K | 833K | 541.8K | |
| Selling General Administrative | 4.6M | 10.5M | 18.9M | 20.8M | 20.8M | 14.5M | |
| Other Operating Expenses | 20.8M | 57.0M | 56.6M | 68.7M | 75.6M | 53.2M | |
| Operating Income | (20.8M) | (57.0M) | (56.6M) | (68.7M) | (75.6M) | (79.4M) | |
| Net Income From Continuing Ops | (19.7M) | (56.4M) | (56.6M) | (67.3M) | (68.2M) | (71.6M) | |
| Ebit | (20.8M) | (57.0M) | (57.0M) | (68.7M) | (75.6M) | (79.4M) | |
| Research Development | 16.2M | 46.5M | 37.7M | 47.8M | 54.8M | 38.7M | |
| Ebitda | (20.7M) | (56.8M) | (56.0M) | (67.9M) | (74.8M) | (78.6M) | |
| Total Operating Expenses | 20.8M | 57.0M | 56.6M | 68.7M | 75.6M | 53.2M | |
| Reconciled Depreciation | 83K | 217K | 674K | 744K | 822K | 470.4K | |
| Income Before Tax | (19.7M) | (56.4M) | (56.6M) | (67.1M) | (71.2M) | (74.7M) | |
| Total Other Income Expense Net | 1.1M | 617K | 22K | 1.6M | 4.5M | 4.7M | |
| Net Income Applicable To Common Shares | (19.7M) | (56.4M) | (56.6M) | (67.1M) | (60.4M) | (63.4M) | |
| Net Income | (18.6M) | (55.8M) | (56.4M) | (65.4M) | (71.2M) | (74.7M) | |
| Income Tax Expense | (1.1M) | (587K) | (211K) | (1.6M) | (1.5M) | (1.4M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.